SP Plus (NASDAQ:SP) reported quarterly earnings of $0.42 per share which missed the analyst consensus estimate of $0.67 by 37.31 percent. This is a 14.29 percent decrease over earnings of $0.49 per share from the same period last year.
BTIG Initiates Coverage On Keros Therapeutics with Buy Rating, Announces Price Target of $80
BTIG analyst Julian Harrison initiates coverage on Keros Therapeutics (NASDAQ:KROS) with a Buy rating and announces Price Target of $80.